Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurogen commences trial of insomnia drug
The phase II clinical trial is designed to determine the efficacy of four dose levels of NG2-73 compared to placebo in reducing the time it takes to fall
The phase II clinical trial is designed to determine the efficacy of four dose levels of NG2-73 compared to placebo in reducing the time it takes to fall
Maxygen established the alliance with Roche in May 2003 in which Roche licensed worldwide commercialization rights to specific novel interferon alpha product candidates developed by Maxygen for hepatitis
The written agreement specifies the terms and conditions under which Nuvelo will conduct and analyze the pivotal phase III trial in support of a regulatory submission. The trial,
Treatment with a combination of Zadaxin and pegylated interferon alpha did not demonstrate a statistically significant benefit compared to treatment with pegylated interferon alone in sustained viral response
The company said that it expects to submit an investigational new drug application for an RNAi therapeutic for the treatment of pandemic flu as early as the end
The technology includes specific Fc (antibody constant region) variants that complement Xencor’s proprietary suite of XmAb engineered Fc domains, which are designed to enhance the therapeutic properties of
Merck has gained access to MorphoSys’ proprietary technologies, HuCal gold and AutoCal, for use in its drug discovery programs, and will be able to develop HuCal-derived therapeutic antibodies
MN-001, a small molecule inhibitor of inflammatory mechanisms known to be involved in asthma, was evaluated in a randomized, double-blind, placebo-controlled multi-center phase II clinical trial in patients
In this eight-week study, Cymbalta, a serotonin and norepinephrine reuptake inhibitor, was effective in reducing depression symptoms by two weeks for 42% of patients. Within the same time
Radius has also acquired the rights to the analogs of the molecule, along with rights to several Ipsen novel formulation technologies. The license is on a worldwide basis